← Back to Clinical Trials
Recruiting NCT07455201

NCT07455201 Evaluating a Prototype CT Scan for ICH Evacuation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07455201
Status Recruiting
Phase
Sponsor Icahn School of Medicine at Mount Sinai
Condition Intracerebral Hemorrhage
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2025-10-31
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
DynaCT MultiphaseDynaCT Sine Spin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2025-10-31 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the project is to collect pre-procedural CT scans, intra-procedural post-evacuation scans as well as immediate post-procedural CT scans to evaluate and collect feedback of two Siemens prototypes: 1) perfusion prototype and 2) automatic hemorrhage detection prototype. The assessment of the prototypes, including its features will focus on the feasibility, usefulness as well as the potential clinical value add in minimally invasive ICH treatment.

Eligibility Criteria

Inclusion Criteria: * Patient ≥ 18 years old * Patient is planned to undergo minimally invasive hemorrhage evacuation at Mount Sinai West Hospital Exclusion Criteria: * Patient is \< 18 years old * Patient is not planned to undergo minimally invasive hemorrhage evacuation at Mount Sinai West Hospital

Contact & Investigator

Central Contact

Emily Svendsen

✉ Emily.Svendsen@mountsinai.org

📞 212-241-3238

Principal Investigator

Christopher Kellner

PRINCIPAL INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Frequently Asked Questions

Who can join the NCT07455201 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Intracerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07455201 currently recruiting?

Yes, NCT07455201 is actively recruiting participants. Contact the research team at Emily.Svendsen@mountsinai.org for enrollment information.

Where is the NCT07455201 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT07455201 clinical trial?

NCT07455201 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Christopher Kellner at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 15 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology